| Budget Amount *help |
¥205,140,000 (Direct Cost: ¥157,800,000、Indirect Cost: ¥47,340,000)
Fiscal Year 2021: ¥36,400,000 (Direct Cost: ¥28,000,000、Indirect Cost: ¥8,400,000)
Fiscal Year 2020: ¥34,840,000 (Direct Cost: ¥26,800,000、Indirect Cost: ¥8,040,000)
Fiscal Year 2019: ¥36,920,000 (Direct Cost: ¥28,400,000、Indirect Cost: ¥8,520,000)
Fiscal Year 2018: ¥44,200,000 (Direct Cost: ¥34,000,000、Indirect Cost: ¥10,200,000)
Fiscal Year 2017: ¥52,780,000 (Direct Cost: ¥40,600,000、Indirect Cost: ¥12,180,000)
|
|---|
| Outline of Final Research Achievements |
Architecturally complex natural products with molecular weight of over 500 often exhibit potent bioactivities, and represent privileged structures for the development of pharmaceuticals. We achieved many total syntheses of the complex terpenes, nucleosides, and peptides. The developed strategies and tactics significantly simplified the synthetic routes to the natural products, thereby facilitating their practical preparations. Furthermore, a medicinally relevant chemical space was expanded by the preparation of numerous natural product analogues, leading to the discovery of new artificial analogues with higher or disparate bioactivities. Structure-activity relationship studies of these analogues enabled us to determine biologically significant structural features and to elucidate their mode of actions. The thus-obtained results together will serve as valuable information for the synthesis and design of novel molecules with more potent and selective biological activities.
|
